^
Association details:
| Biomarker: | VIM expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Vimentin expression correlates with immune-checkpoint inhibitor efficacy in non-small cell lung cancer
Published date:
04/06/2023
Excerpt:
This retrospective multicenter study enrolled patients with NSCLC who received ICI treatment...In patients treated with ICI monotherapy, ORR, PFS, and OS were significantly better in the vimentin-positive group (10%-49%) than in the vimentin-negative group (<10%) (54% vs. 25%, p = .003, median = 7.9 vs. 3.2 months, p = .011; median = 27.0 vs. 13.6 months, p = .015, respectively).
DOI:
10.1002/cncr.34782
